Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington’s chorea – an underserved indication with ...

Medically reviewed by Nicholas R. Metrus, MD Tardive dyskinesia and dystonia are both neurological disorders that can affect ...

A team led by UT Southwestern Medical Center researchers has uncovered the atomic structure of a protein complex pivotal to ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric ...

Tremors, stiffness, and slowed movement are classic signs of Parkinson's disease. Learn more about the signs and symptoms of Parkinson's disease.

A team led by UT Southwestern Medical Center researchers has uncovered the atomic structure of a protein complex pivotal to ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best strong buy healthcare stocks to buy now. On July 22, Morgan ...

Laycock underwent the procedure last year and recently received an upgrade to adaptive deep brain stimulation (ADBS), which ...

On June 25, 2025 and June 30, 2025, Supernus and Sage, respectively, filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust ...

The drug could help tackle symptoms of schizophrenia without causing side effects common with dopamine-acting drugs like olanzapine and risperidone, such as weight gain, movement disorders ...

AbbVie has launched its Produodopa for Parkinson’s in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the disease.

The second international consensus conference on the scapula was held in Lexington Kentucky. The purpose of the conference was to update, present and discuss the accumulated knowledge regarding ...